Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates, Lot to Lot Consistency and Antigen Interference With Co-Administered EPI Vaccines (Phase III)

RV 0319

This phase III trial aims to assess the efficacy, safety and immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in neonates, lot-to-lot consistency, and antigen interference with co-administered EPI vaccines

2020-10-30

2022-04-30

2023-05-30

Completed

Early phase I

1400

Inclusion Criteria: 1. Neonate 0-5 days (0-144 hours) of age at the time of first dose. 2. Neonate is in good health as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator. 3. The neonate was born full term (minimum of 37 completed weeks and maximum of 42 completed weeks gestation). 4. Neonate birth weight 2500-4000 g inclusive. 5. Parent or guardian has been informed properly regarding the study and signed the informed consent form. 6. Parent or guardian commits to comply with the instructions of the investigator and the schedule of the trial. Exclusion Criteria: 1. Subject concomitantly enrolled or scheduled to be enrolled in another trial. 2. The subject has direct relatives relationship with the study team. 3. The subject has evolving mild, moderate or severe illness, especially infectious diseases or fever (body temperature 37.5°C) within the 48 hours preceding enrollment. 4. Subject with a known or suspected history of allergy to any component of the vaccines (based on anamnesis). 5. Subject with a biological mother with a known or suspected human immunodeficiency virus (HIV) or Hepatitis B infection. 6. Subject with known or suspected major congenital malformations or genetically determined disease. 7. Subject with intussusception. 8. Subject with a known or suspected disease of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy. 9. Subject with a known or suspected disease of the immune system or those who have received immunosuppressive therapy, including immunosuppressive courses of systemic corticosteroid. 10. Subject who have ever received any blood products, including immunoglobulin, or for whom receipt of any blood product is anticipated during the course of study. 11. Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives. 12. Subject immunized with non-EPI vaccines. 13. Gastroenteritis in the 24 hours preceding dosing (temporary exclusion criteria). 14. Subject planning to move from the study area before the end of the study period.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 1400, 'type': 'ACTUAL'}}

2023-11-29